(183 days)
Not Found
No
The device description and performance studies focus on mechanical and physical principles (Boyle's Law, pressure transduction, mechanical anchoring) and standard biocompatibility/performance testing. There is no mention of AI, ML, image processing, or data analysis that would suggest the use of such technologies.
No.
The device is described as a monitoring system that measures intracranial pressure and can facilitate CSF drainage. While CSF drainage might alleviate symptoms, the primary stated function relating to patient management is measurement, not direct therapeutic intervention.
Yes.
The device's intended use is to "direct measurement of intracranial pressure," which is a diagnostic purpose to assess a patient's condition.
No
The device description clearly details multiple hardware components including a bolt, catheter, pressure transducer, cable, probe guide, and stylet. It is not solely software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens (like blood, urine, or tissue) taken from the human body to provide information for diagnosis, monitoring, or screening. This testing is performed outside of the body (in vitro).
- Device Function: The ACT II MP Monitoring System directly measures intracranial pressure within the patient's body (in vivo). It involves inserting a catheter and bolt into the skull.
- Intended Use: The intended use clearly states "direct measurement of intracranial pressure in patients" and potential CSF drainage. This is an in-vivo procedure.
Therefore, the device's function and intended use fall outside the scope of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The use of the ACT II MP Monitoring System by a qualified neurosurgeon is indicated when direct measurement of intracranial pressure is required and when the patient may require CSF drainage in the course of their care or when data from a second parameter may be deemed useful in optimum patient management.
Product codes (comma separated list FDA assigned to the subject device)
HCA
Device Description
The ICP monitor uses a bolt anchored in the skull. The bolt holds an air-column catheter with a flaccid bladder on the distal end. The proximal end of the catheter is attached to a pressure transducer placed in the distal end of a standard cable. The cable can be attached directly to any patient monitor. The ICP monitoring technology is based on Boyle's law. The bladder volume changes to accommodate PTV =P2V2 The pressure in the bladder, catheter and transducer thereby mirrors that of ICP. The air required to activate the bladder is introduced into the bladder when a piston on the proximal end of the catheter is joined to a cylinder on the transducer housing. The bladder air is replaced once per shift by removing and replacing the transducer housing on the piston.
A probe guide is incorporated into the cap placed on the bolt at the factory and into the cap that accompanies the drainage catheter. The guides direct the path of a probe inserted through the cap/bolt. The guide tube does not enter the brain but stops just above the drill hole. Both caps provide a compression fitting that secures and seals the probe to the cap.
The catheter is a single lumen catheter. A preloaded stylet is used for catheter insertion and placement. A luer connector is provided to connect the catheter to a standard CSF collection system.
The bolt provides an access port through which a ventricular catheter can be introduced if drainage is needed. Should drainage of CSF be indicated, the top cap of the bolt is removed and the ACT II Ventricular Catheter is inserted into a ventricle. Once the catheter is in place, a preinstalled elastomeric sleeve and compression cap are moved down the catheter to the bolt. The cap compresses the sleeve against the bolt and catheter anchors the catheter in place.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
brain / skull
Indicated Patient Age Range
Not Found
Intended User / Care Setting
qualified neurosurgeon
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Animal and Laboratory testing:
- The subject device meets AAMI performance standards.
- Animal test data of the subject device vs. a ventricular catheter shows the device faithfully follows the ventricular pressure and waveform and that the bolt is securely anchored in the skull.
Safety:
- Mechanical integrity: Laboratory testing and basic design assure that no parts will come loose and be left in the patient. The interference rib design provides a secure come foose and on the profession fitting is capable of securing a probe and providing an effective seal.
- Biocompatibility: The materials used in the ACT II MP ICP Monitoring System and ACT II MP Ventricular Catheter that come in contact with the body System and ACT II ICP Monitoring System and ACT II ICP Monitoring System and ACT II Ventricular Catheter.
Effectiveness:
- Accuracy: The ICP monitoring system meets AAMI standards for accuracy and performance.
- Ease of use: The catheter is mounted in a bolt, as is the predicate device ICP monitor. The probe inserted into the bolt is held in place by a compression device in the same manner as the predicate probe introduction device.
- Setup: There is no need to precondition or calibrate the system beyond the normal 2 Sec a - The transducer. The transducer connects directly to any patient monitor.
- Operating life: The IFU requires that the air in the bladder be replaced every shift.
- Trouble-shooting: Unlike other in-situ systems, the transducer function and patient monitor zero can be checked at any time.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 882.4100 Ventricular catheter.
(a)
Identification. A ventricular catheter is a device used to gain access to the cavities of the brain for injection of material into, or removal of material from, the brain.(b)
Classification. Class II (performance standards).
0
K013005
1/4
510(k) Summary Section 2.0
2.1 Submitted by InnerSpace FAX 949 752 8673 Phone 949 752 8672 2293 South Pullman Street, Suite A Santa Ana, CA. 92705 Contact: Donald E. Bobo ext 12 Prepared Sept. 4, 2001
This submittal covers a modification to ACT II, 510(k) K010422. The modification adds the This Submittan Covers a mountedated to 10 110 the device and into the brain via a guide tube. The ability to hisen a momitoring proov and one of thing. The submittal is therefore identical to proce is new in the guide table of a compressed to incorporating a guide tube and STOR) 11010 122 except for changes in labeling related to model number and compression thing and except for changes and naragraphs or portions of a paragraph that have indications for use. In order to cash 500k) K010422 submittal, new text has been changed to this color for ease of locating new material.
The modification incorporates a guide tube and compression fitting in the bolt cap to allow The modification and retention of a probe . 7 to .9 mm (028 to .036") in diameter. The device is the miser.on and recention of a prooo .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . capable of measuring ICP and a second parameter such as tissue pO2.
The MP system is essentially unchanged from ACT II 510(k) K010422 other than placing a The Mr "Systom is ease.inaily concertain cap and bolt changes that provide proper guide tube in the cap and moorporating e catheter. There are two caps, the cap that comes on anginnent of the factory and the drainage catheter cap that comes with the drainage catheter the ook from are factory. Both caps provide a guide tube that directs the path of a probe inserted through the cap/bolt. The guide tube does not enter the brain. It simply guides an inserted unvage to a point above the dura. The cap and guide tube are similar in function to the prooc to a point access the assactived in predicate device 510(k) K002765- by Licox. The rest of the mirodator kits doserious in prodicate device 510(k) K010422 - ACT II by InnerSpace
For ease of reading, ACT II will be referred to throughout as the basic system and the MP version of ACT II, as the MP.
ICP Monitoring Device Name 2.2
- Trade name 2.2.1
- 2.2.2 Common name
- Classification name 2.2.2
ACT II MP ICP Monitoring System Intracranial Pressure Monitoring Device Intracranial Pressure Monitoring Device CFR 882.1620 (84GWM)
Ventricular Catheter Name 2.3
- Trade name 2.3.1
- Common name 2.3.2
- Classification name 2.3.3
ACT II MP Ventricular Catheter Ventricular Catheter Ventricular Catheter CFR 882.4100 (84HCA)
1
2.4 Equivalent device
The ACT II MP ICP Monitoring System is a substantially equivalent device to the ACT II ICP Monitoring System 510(k) K010422 by InnerSpace and to the introducer kits described in 510(k) K002765 by Licox.
2.5 Description of the ICP Monitoring Device
The ICP monitor uses a bolt anchored in the skull. The bolt holds an air-column catheter with a flaccid bladder on the distal end. The proximal end of the catheter is attached to a pressure transducer placed in the distal end of a standard cable. The cable can be attached directly to any patient monitor. The ICP monitoring technology is based on Boyle's law. The bladder volume changes to accommodate PTV =P2V2 The pressure in the bladder, catheter and transducer thereby mirrors that of ICP. The air required to activate the bladder is introduced into the bladder when a piston on the proximal end of the catheter is joined to a cylinder on the transducer housing. The bladder air is replaced once per shift by removing and replacing the transducer housing on the piston
2.6 Description of the probe guide
A probe guide is incorporated into the cap placed on the bolt at the factory and into the cap that accompanies the drainage catheter. The guides direct the path of a probe inserted through the cap/bolt. The guide tube does not enter the brain but stops just above the drill hole. Both caps provide a compression fitting that secures and seals the probe to the cap.
2.7 Description of the Ventricular Catheter
The catheter is a single lumen catheter. A preloaded stylet is used for catheter insertion and placement. A luer connector is provided to connect the catheter to a standard CSF collection system.
The bolt provides an access port through which a ventricular catheter can be introduced if drainage is needed. Should drainage of CSF be indicated, the top cap of the bolt is removed and the ACT II Ventricular Catheter is inserted into a ventricle. Once the catheter is in place, a preinstalled elastomeric sleeve and compression cap are moved down the catheter to the bolt. The cap compresses the sleeve against the bolt and catheter anchors the catheter in place.
The intent of the basic system design is to provide a minimally invasive ICP monitoring device to which a drainage capability can be added if needed. The intent of the MP system is to add a probe guide to the basic system. The probe guide can be seen in the graphics following the text of Section 5. For purposes of clarity, the graphics portraying the approved predicate device will be identified as the basic device. The graphics of the new device will be identified to as the MP device. A catheter capable of measuring another parameter, such as tissue oxygen, that may be inserted into the brain through the cap will be referred to as a probe.
Pressure sensor
The pressure sensor, its mounting and use are unchanged
Transducer housing
The housing that engages the bolt is unchanged.
2
2.7 Intended Use of the Device
The device is to be used in patients who require continuous ICP monitoring, who may require drainage of CSF and who may require monitoring of a second parameter such as tissue oxygen.
2.8 Device Characteristics vs. Predicate Device The characteristics of the Basic device vs. the MP device are shown in Table 1.
Table 1 | |||
---|---|---|---|
Characteristic | ACT II Basic | ACT II MP | Comment |
Bolt diameter | .250" | .250" | No change |
Skull Attachment | Ribs | Ribs | No change |
Pressure sensor OD | 1.5 mm | 1.5 mm | No change |
Pressure catheter bladder mount | PVC | PVC | No change |
Pressure catheter bladder | Butyl | Butyl | No change |
Microbore tube material in brain | |||
(housed within bladder) | Polyimide | Polyimide | No change |
Depth of bladder in brain | 1.3 cm | 1.3 cm | No change |
Probe guide (not in the brain) | N/A | Stainless steel | New feature |
Ventricular Catheter OD | 2.5 mm | 2.5 mm | No change |
Ventricular Catheter ID | 1.5 mm | 1.5 mm | No change. |
Catheter material | Tecoflex EG-80A | Tecoflex EG-80A | No change |
Depth of ventricular catheter | |||
in brain | 6-8 cm | 6-8 cm | No change |
Bacteria barrier | Betadine on bolt/skull | Betadine on bolt/skull | No change |
Probe catheter diameter | N/A | 0.7 to 0.9 mm | See Note |
Table
Note: The introducer kit in predicate device 510(k) K002765 receives an oxygen probe 0.8 mm diameter.
2.9 Animal and Laboratory testing:
- The subject device meets AAMI performance standards. .
- t Animal test data of the subject device vs. a ventricular catheter shows the device faithfully follows the ventricular pressure and waveform and that the bolt is securely anchored in the skull.
The biocompatibility of the ACT II ICP Monitoring System related to the bolt was tested per ISO 10993-1-1994 Biological Evaluation of Medical Devices - Part 1: Guidance on the Selection of Tests and the FDA General Program Memorandum No. G95-1. The material used in the catheter is Tecoflex EG-80A.
Conclusion
The ACT II MP ICP Monitoring System, in combination with the ISM -3000 series cable, and the ACT II MP Ventricular Catheter are equivalent to the predicate devices (510(k) K010422 and 510(k) K002765) because:
3
1 2014 12 12
Intended Use
The system has the same basic intended use, namely to sense intracranial pressure The System has the sume busic interestion accommodates the introduction of a probe and drain CST if necode. The right if the doctor deems the resultant data beneficial to patient management.
Safety
Laboratory testing has shown that the ACT II MP ICP Monitoring System, the Laboratory testing has each and the ISM -3000 series cable or pigtail are safe in the following areas:
· Mechanical integrity · Laboratory testing and basic design assure that no parts will come loose and be left in the patient. The interference rib design provides a secure come foose and on the profession fitting is capable of securing a probe and providing an effective seal.
The materials used in the ACT II MP ICP Monitoring · Biocompatibility System and ACT II MP Ventricular Catheter that come in contact with the body System and ACT II ICP Monitoring System and ACT II ICP Monitoring System and ACT II Ventricular Catheter.
Effectiveness
The ICP monitoring system meets AAMI standards for accuracy and · Accuracy performance.
The catheter is mounted in a bolt, as is the predicate device ICP · Ease of use · Lase of use - The caced into the bolt is held in place by a compression device in the same manner as the predicate probe introduction device.
· Set up There is no need to precondition or calibrate the system beyond the normal 2 Sec a - The transducer. The transducer connects directly to any patient monitor.
· Operating life · The IFU requires that the air in the bladder be replaced every shift. . Operating mr - The 11 - The (disconnecting) and replacing (reconnecting) the transducer to the piston.
· Trouble-shooting · Unlike other in-situ systems, the transducer function and patient monitor zero can be checked at any time.
4
Image /page/4/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with its wings spread, enclosed in a circle. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the top half of the circle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
8 2002 MAR
Mr. Don Bobo Innerspace 2293 South Pullman Street Suite A Santa Ana, California 92705
Re: K013005
Trade/Device Name: ACT II MP ICP Monitoring System Regulation Number: 21 CFR 882.4100 Regulation Name: Intracranial Pressure Monitoring Devices Regulatory Class: Class II Product Code: HCA Dated: January 14, 2002 Received: January 23, 2002
Dear Mr. Bobo:
We have reviewed your Section 510(k) premarket notification of intent to market the device we nave roview your betermined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to conimer to provision of reassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The I ou may, atterest provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it If your de rio to such additional controls. Existing major regulations affecting your device can may or babyer to basil as a subsidians, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean 1 toase be deviloed that I Dr o resum that your device complies with other requirements of the Act that I Dri has Intact a and regulations administered by other Federal agencies. You must or any I caeaal suatures and regeranents, including, but not limited to: registration and listing (21 Comply with an the Act 8 requirements of the manufacturing practice requirements as set OF R Fart 607), accems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
5
Page 2 - Mr. Don Bobo
This letter will allow you to begin marketing your device as described in your Section 510(k) I mis letter will and w you've begal finding of substantial equivalence of your device to a legally premated notification: "The a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 11 you dostre specific arrist arrastic devices), please contact the Office of additionally 21 01 1 1 1 1 1 1 1 1 2 1 1 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -Compinates at (301) 597 - the Office of Compliance at (301) 594-4639. Also, please note the your actitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Oiner gonetal international and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely yours,
iriam C. Provost
for Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Indications for Use Statement
210(k) Number Device Name
013005
ACT II MP ICP Monitoring system
Indications
The use of the ACT II MP Monitoring System For Use Indications by a qualified neurosurgeon is indicated when direct measurement of intracranial pressure in oy a quantion incursours and when the patient may require CSF drainage in the course of their care or when data from a second parameter may be deemed useful in optimum patient management.
Please do not write below this line
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109)
Or
Over-The Counter Use _________________________________________________________________________________________________________________________________________________________
Miriam C. Provost
Division of General. Restorative and Neurological Devices
510(k) Number K013005